Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting
for> 6 weeks with onset before 16 years of age. JIA is the most common chronic …

Due to the key role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of
immunoinflammatory diseases, TNF-α inhibitors have been successfully developed and …

Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced
cancer and have emerged as a pillar of standard cancer care. However, their use is …

Background Early diagnosis and treatment of juvenile idiopathic arthritis (JIA) with
conventional and biologic disease-modifying anti-rheumatic drugs have vastly improved …

Introduction The management of a child with juvenile idiopathic arthritis (JIA) requires a
combination of pharmacological, physical, and psychosocial therapies in order to induce …

Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept,
golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune …

Introduction Psoriasis is a chronic-immune-mediated disease affecting 2–4% of the western
population. The disease is associated with several co-morbidities including an increased …

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with
extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA) …

Objective Biologics have an important role in the treatment of juvenile idiopathic arthritis
(JIA). Long‐term safety data are limited. Direct comparison of different agents regarding …

Background Tumor necrosis factor (TNF)-α inhibitors represented by Etanercept (a fusion
protein containing soluble TNF receptor II (sTNFRII) and the Fc segment of human IgG1) …